Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apyx Medical (APYX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Apyx Medical (APYX) over the last 15 years, with Q3 2025 value amounting to 6.46%.

  • Apyx Medical's EBITDA Margin rose 251800.0% to 6.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.84%, marking a year-over-year increase of 246000.0%. This contributed to the annual value of 39.18% for FY2024, which is 62100.0% down from last year.
  • As of Q3 2025, Apyx Medical's EBITDA Margin stood at 6.46%, which was up 251800.0% from 22.63% recorded in Q2 2025.
  • Apyx Medical's 5-year EBITDA Margin high stood at 6.46% for Q3 2025, and its period low was 64.57% during Q1 2024.
  • Its 5-year average for EBITDA Margin is 37.28%, with a median of 38.72% in 2023.
  • As far as peak fluctuations go, Apyx Medical's EBITDA Margin skyrocketed by 1075300bps in 2021, and later crashed by -369900bps in 2022.
  • Quarter analysis of 5 years shows Apyx Medical's EBITDA Margin stood at 10.06% in 2021, then crashed by -368bps to 47.05% in 2022, then increased by 16bps to 39.39% in 2023, then surged by 46bps to 21.43% in 2024, then skyrocketed by 70bps to 6.46% in 2025.
  • Its last three reported values are 6.46% in Q3 2025, 22.63% for Q2 2025, and 32.35% during Q1 2025.